Neuromodulation Devices Global Market- Forecast to 2026

Publishing Date : September, 2019
Report Code : HCMD0131
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Neuromodulation treatment involves direct stimulation or modulation of the nerves by an electrical or magnetic field. It is used as a treatment for unmanageable chronic pain, movement disorders, gastroenterology, urology and others. The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches. This therapy is based on the natural process of stimulation of nerve cell activity and release of neurotransmitters that regulate nerve activity. Neuromodulation is gaining popularity because these devices have been very successful in the treatment of conditions for which medicines have failed completely or may have unpleasant side effects.

An estimated by IQ4I Research, the neuromodulation devices global market is expected to reach $9,917.0 million by 2026 growing at a high single digit CAGR from 2019 to 2026 due to increasing incidence of chronic pain, increasing Parkinson’s and Alzheimer’s disorders, low approval rate of CNS drugs, favorable reimbursement scenario in major markets, the emergence of neuromodulation as add-on therapy, technological innovations, rise in the number of clinical studies performed and expansion in emerging markets. The neuromodulation devices market is segmented by product, application, end-user, and geography.

Based on the product the neuromodulation global market is segmented into internal neuromodulation and external neuromodulation devices. Internal neuromodulation devices segment accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026. Internal neuromodulation devices market is segmented into spinal cord stimulator (SCS), deep brain stimulator (DBS), sacral nerve stimulator (SNS), vagus nerve stimulator (VNS) and others. Among internal neuromodulation devices, Spinal cord stimulator (SCS) segment accounted for the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 due to increase in the incidence of chronic pain, increase in movement disorders and high implantation rate of spinal cord stimulators. The external neuromodulation devices market is segmented into transcutaneous electrical nerve stimulator (TENS), neuromuscular electrical stimulator (NMES) and others. Among external neuromodulation devices, transcutaneous electrical nerve stimulation (TENS) segment accounted for the largest revenue in 2019 and is expected to grow at a low single digit CAGR from 2019 to 2026.

Based on the application, the neuromodulation devices global market is segmented into pain management, central nervous system, gastroenterology and urology, and other disorders (respiratory, Sleep Apnea, obesity and diabetic neuropathy). Among application, pain management segment accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026. Pain management is further segmented into chronic pain, failed back surgery syndrome, and others (migraine, and ischemia). Among pain management, chronic pain segment accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026 due to increasing incidence of chronic pain, increasing utilizing of the spinal cord stimulators, and advancement in neuromodulation devices.

Central nervous system is further segmented into Parkinson’s disorders, essential tremor, dystonia, epilepsy, depression, and others (Obsessive-compulsive disorder (OCD) and anxiety). Among Central nervous system disorders, Epilepsy segment accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026. Gastroenterology and Urology is further segmented into gastroparesis, urinary incontinence, and fecal incontinence. Among Gastroenterology and Urology urinary incontinence segment accounted for the largest revenue in 2019 and is expected to grow at a mid-single digit CAGR from 2019 to 2026.

Based on the end-user, the neuromodulation devices global market is segmented into hospitals and ambulatory surgery centers, clinics and physiotherapy centers and Academics and research. Among end-user, Hospitals and ambulatory surgery centers accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026.

Based on the region, the neuromodulation devices global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and Middle East & others). North America accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026 due to high technological advancements, increased growing awareness about medical care, treatment style, increase in the aging population, strong product pipeline, new indications, investments and funds, increases in neurological diseases, sophisticated infrastructure related to healthcare and high expenditure present among the population of North America are boosting the market of neuromodulation devices.

The Asia-Pacific is the fastest growing region with a double digit CAGR from 2019 to 2026 due to rising incidences of neurological disorders, government initiatives to increasing awareness by education campaigns, large pool of patients, increasing geriatric population, advancements in surgeries and technologies, increased healthcare facilities, increasing adoption of implantable devices, high acceptance of technological advancements, the easy availability of advanced healthcare technology, skilled personnel and low-cost for the surgery are driving the market.

The neuromodulation devices global market is a highly consolidated market hence all the existing players in this market are involved in developing new and advanced technologies to maintain their market shares. Some of the major players in Neuromodulation devices market include Medtronic Plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), LivaNova Plc (U.K.), Nevro Corporation (U.S.), Inspire Medical System, Inc. (U.S.), Nuvectra (U.S.), Neuropace Inc. (U.S.), Bioness Inc. (U.S.), Beijing PINS Medical Co., Ltd. (China), Laborie Medical (Canada) and Neuronetics, Inc. (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • U.K.
  • Rest of Europe
  • Asia-Pacific 
  • Japan
  • China
  • India
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and Others
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING INCIDENCE OF CHRONIC PAIN
        • 3.3.1.2     INCREASING PARKINSON’S AND ALZHEIMER’S DISORDER’S
        • 3.3.1.3     LOW APPROVAL RATE OF CNS DRUGS IS DRIVING NEUROMODULATION MARKET
        • 3.3.1.4     FAVORABLE REIMBURSEMENT SCENARIO IN MAJOR MARKETS
        • 3.3.1.5     THE EMERGENCE OF NEUROMODULATION AS ADD ON THERAPY
        • 3.3.1.6     TECHNOLOGICAL INNOVATIONS IN NEUROMODULATION
        • 3.3.1.7     EXPANSION IN EMERGING MARKETS
        • 3.3.1.8     THE RISE IN THE NUMBER OF CLINICAL STUDIES PERFORMED
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     SIDE EFFECTS AND RISKS ASSOCIATED WITH THE USE
        • 3.3.2.2     LACK OF TRAINED PROFESSIONALS
        • 3.3.2.3     AVAILABILITY OF ALTERNATIVE TREATMENTS
        • 3.3.2.4     STRINGENT REGULATORY GUIDELINES
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 13485 MEDICAL DEVICES
        • 3.4.1.3     ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     EUROPE
      • 3.4.5     JAPAN
      • 3.4.6     CHINA
      • 3.4.7     INDIA
    • 3.5     CLINICAL TRIALS DATA
    • 3.6     TECHNOLOGICAL ADVANCEMENTS
      • 3.6.1     RECHARGEABLE SYSTEMS
      • 3.6.2     OPTOGENETIC TECHNOLOGY
      • 3.6.3     FOCUSED ULTRASOUND (FUS)
      • 3.6.4     MINIATURIZATION
      • 3.6.5     PORTABLE NUEROMODULATION SYSTEMS (PONS)
      • 3.6.6     WEARABLE PAIN MANAGEMENT TECHNOLOGY
      • 3.6.7     TRANS-SPINAL DIRECT CURRENT STIMULATION (TSDCS)
      • 3.6.8     NANO-NEUROMODULATION
      • 3.6.9     BIOACTIVE COATINGS
    • 3.7     PORTER’S FIVE FORCE ANALYSIS
      • 3.7.1     THREAT OF NEW ENTRANTS
      • 3.7.2     THREAT OF SUBSTITUTES
      • 3.7.3     BARGAINING POWER OF SUPPLIERS
      • 3.7.4     BARGAINING POWER OF BUYERS
      • 3.7.5     COMPETITIVE RIVALRY
    • 3.8     SUPPLY CHAIN ANALYSIS
    • 3.9     REIMBURSEMENT SCENARIO
      • 3.9.1     REIMBURSEMENT TABLE
    • 3.10     REGULATORY APPROVED NEUROMODULATION DEVICES
      • 3.10.1     SPINAL CORD STIMULATORS (SCS)
      • 3.10.2     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS)
      • 3.10.3     DEEP BRAIN STIMULATION (DBS)
      • 3.10.4     SACRAL NERVE STIMULATION (SNS)
      • 3.10.5     VAGUS NERVE STIMULATION (VNS)
      • 3.10.6     TRANSCRANIAL MAGNETIC STIMULATION (TMS)
    • 3.11     FUNDING SCENARIO
    • 3.12     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.12.1     NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS
      • 3.12.2     SPINAL CORD STIMULATORS GLOBAL MARKET SHARE ANALYSIS
      • 3.12.3     DEEP BRAIN STIMULATORS GLOBAL MARKET SHARE ANALYSIS
    • 3.13     NEUROMODULATION DEVICES NUMBER OF UNITS BY REGION
      • 3.13.1     SPINAL CORD STIMULATION (SCS) NUMBER OF UNITS BY REGION
      • 3.13.2     DEEP BRAIN STIMULATION (DBS) NUMBER OF UNITS BY REGION
      • 3.13.3     SACRAL NERVE STIMULATION (SNS) NUMBER OF UNITS BY REGION
      • 3.13.4     VAGUS NERVE STIMULATION (VNS) NUMBER OF UNITS BY REGION
      • 3.13.5     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) NUMBER OF UNITS BY REGION
      • 3.13.6     NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) NUMBER OF UNITS BY REGION
    • 3.14     MARKET PENETRATION
    • 3.15     NEUROMODULATION DEVICES COMPANY COMPARISON TABLE BY REVENUE, TECHNOLOGY, PRODUCTS AND APPLICATION
  • 4     NEUROMODULATION DEVICES GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     INTERNAL NEUROMODULATION DEVICES
      • 4.2.1     SPINAL CORD STIMULATION (SCS)
      • 4.2.2     DEEP BRAIN STIMULATION (DBS)
      • 4.2.3     SACRAL NERVE STIMULATION (SNS)
      • 4.2.4     VAGUS NERVE STIMULATION (VNS)
      • 4.2.5     OTHER INTERNAL NEUROMODULATION DEVICES
        • 4.2.5.1     GASTRIC ELECTRIC STIMULATION (GES)
        • 4.2.5.2     RESPIRATORY ELECTRICAL STIMULATION (RES)/PHRENIC NERVE STIMULATION (PNS)
        • 4.2.5.3     HYPOGLOSSAL NERVE STIMULATION (HGNS)
    • 4.3     EXTERNAL NEUROMODULATION DEVICES
      • 4.3.1     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
      • 4.3.2     NEUROMUSCULAR ELECTRICAL STIMULATION (NMES)
      • 4.3.3     OTHER EXTERNAL NEUROMODULATION DEVICES
        • 4.3.3.1     TRANSCRANIAL MAGNETIC STIMULATION (TMS)
        • 4.3.3.2     FUNCTIONAL ELECTRICAL STIMULATION (FES)
        • 4.3.3.3     ELECTRO CONCLUSIVE THERAPY (ECT)
        • 4.3.3.4     PERCUTANEOUS TIBIAL NERVE STIMULATION (PTNS)
        • 4.3.3.5     PORTABLE NEUROMODULATION STIMULATOR (PONS)
        • 4.3.3.6     TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
        • 4.3.3.7     TRANSCRANIAL ALTERNATING CURRENT STIMULATION (TACS)
        • 4.3.3.8     TRIGEMINAL NERVE STIMULATION (TNS)
  • 5     NEUROMODULATION DEVICES GLOBAL MARKET, BY APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     PAIN MANAGEMENT
      • 5.2.1     CHRONIC PAIN
      • 5.2.2     FAILED BACK SURGERY SYNDROME (FBSS)
      • 5.2.3     OTHER PAIN MANAGEMENT
    • 5.3     CENTRAL NERVOUS SYSTEM (CNS)
      • 5.3.1     PARKINSON'S DISEASE
      • 5.3.2     ESSENTIAL TREMORS
      • 5.3.3     DYSTONIA
      • 5.3.4     EPILEPSY
      • 5.3.5     DEPRESSION
      • 5.3.6     OTHER CNS
    • 5.4     GASTROENTEROLOGY AND UROLOGY
      • 5.4.1     GASTROPARESIS
      • 5.4.2     URINARY INCONTINENCE
      • 5.4.3     FAECAL INCONTINENCE
    • 5.5     OTHER APPLICATIONS
  • 6     NEUROMODULATION DEVICES GLOBAL MARKET, BY END-USERS
    • 6.1     INTRODUCTION
    • 6.2     HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC)
    • 6.3     CLINICS AND PHYSIOTHERAPY CENTERS
    • 6.4     ACADEMICS AND RESEARCH
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     U.K.
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     INDIA
      • 7.4.4     REST OF APAC
    • 7.5     ROW
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATAM
      • 7.5.3     MIDDLE EAST AND OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     PRODUCT APPROVAL
    • 8.3     NEW PRODUCT LAUNCH
    • 8.4     AGREEMENTS AND PARTNERSHIPS
    • 8.5     OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     ABBOTT LABORATORIES
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     BEIJING PINS MEDICAL CO., LTD.
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BIONESS, INC.
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     BOSTON SCIENTIFIC CORPOARTION
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     INSPIRE MEDICAL SYSTEM, INC.
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     LABORIE MEDICAL TECHNOLOGIES, INC. (COGENTIX MEDICAL)
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     LIVANOV PLC (SORIN GROUP)
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     MEDTRONIC PLC
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     NEVRO CORPOARTION
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     NEUROPACE, INC.
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS
    • 9.11     NUVECTRA CORPORATION
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     PRODUCT PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     BUSINESS STRATEGY
      • 9.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 2     SCS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 3     DBS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 4     SNS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 5     VNS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 6     TENS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 7     NMES NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 8     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 9     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 10     INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 11     INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 12     SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 13     DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 14     SACRAL NERVE STIMULATION (SNS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 15     VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 16     OTHER INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 17     EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 18     EXTERNAL NEUROMODULATION DEVICESGLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 19     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 20     NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 21     OTHER EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 22     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 23     PAIN MANAGEMENT GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 24     PAIN MANAGEMENT GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 25     CHRONIC PAIN GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 26     FAILED BACK SURGERY SYNDROME (FBSS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 27     OTHER PAIN MANAGEMENT GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 28     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 29     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 30     PARKINSON'S DISEASE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 31     ESSENTIAL TREMORS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 32     DYSTONIA GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 33     EPILEPSY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 34     DEPRESSION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 35     OTHERS GLOBAL MARKET REVENUE,VBY REGION, (2018-2026) ($MN)
      • TABLE 36     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 37     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 38     GASTROPARESIS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 39     URINARY INCONTINENCE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 40     FAECAL INCONTINENCE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 41     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 42     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
      • TABLE 43     HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 44     CLINICS AND PHYSIOTHERAPY CENTERS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 45     ACADEMICS AND RESEARCH GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 46     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 47     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 48     NORTH AMERICA INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 49     NORTH AMERICA EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 50     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 51     NORTH AMERICA PAIN MANAGEMENT MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 52     NORTH AMERICA CENTRAL NERVOUS SYSTEM MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 53     NORTH AMERICA GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 54     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
      • TABLE 55     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 56     EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 57     EUROPE INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 58     EUROPE EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 59     EUROPE NEUROMODULATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 60     EUROPE PAIN MANAGEMENT MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 61     EUROPE CENTRAL NERVOUS SYSTEM MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 62     EUROPE GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 63     EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
      • TABLE 64     EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 65     APAC NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 66     APAC INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 67     APAC EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 68     APAC NEUROMODULATION DEVICES MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 69     APAC PAIN MANAGEMENT MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 70     APAC CENTRAL NERVOUS SYSTEM MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 71     APAC GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 72     APAC NEUROMODULATION DEVICES MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
      • TABLE 73     APAC NEUROMODULATION DEVICES MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 74     ROW NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 75     ROW INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 76     ROW EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 77     ROW NEUROMODULATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 78     ROW PAIN MANAGEMENT MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 79     ROW CENTRAL NERVOUS SYSTEM MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 80     ROW GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
      • TABLE 81     ROW NEUROMODULATION DEVICES MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
      • TABLE 82     ROW NEUROMODULATION DEVICES MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 83     PRODUCT APPROVAL (2017-2019)
      • TABLE 84     NEW PRODUCT LAUNCH (2017-2019)
      • TABLE 85     AGREEMENTS AND PARTNERSHIPS (2017-2019)
      • TABLE 86     OTHERS (2017-2019)
      • TABLE 87     ABBOTT LABORATORIES : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 88     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 89     ABBOTT LABORATORIES: CARDIOVASCULAR AND NEUROMODULATION, BY SUB-SEGMENT, (2017-2019) ($MN)
      • TABLE 90     ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 91     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 92     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 93     BOSTON SCIENTIFIC CORPORATION: RHYTHM AND NEURO, BY SUB-SEGMENT (2017-2019) ($MN)
      • TABLE 94     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 95     INSPIRE MEDICAL SYSTEM, INC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 96     INSPIRE MEDICAL SYSTEM,INC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 97     LIVANOVA PLC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 98     LIVANOVA PLC: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 99     LIVANOVA PLC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 100     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 101     MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 102     MEDTRONIC, PLC: RESTORATIVE THERAPIES GROUP, BY SUB-SEGMENT (2016-2018) ($MN)
      • TABLE 103     MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 104     NEVRO CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2017-2019) ($MN)
      • TABLE 105     NEVRO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 106     NUVECTRA CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 107     NUVECTRA CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 108     NUVECTRA CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)

      LIST OF FIGURES

      • FIGURE 1     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: NEUROMODULATION DEVICES GLOBAL MARKET
      • FIGURE 3     NEUROMODULATION DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     NEUROMODULATION DEVICES GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     NEUROMODULATION DEVICES GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     NEUROMODULATION DEVICES GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     NEUROMODULATION DEVICES GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     NEUROMODULATION DEVICES: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 11     SPINAL CORD STIMULATOR (SCS) GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 12     DEEP BRAIN STIMULATOR (DBS) GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 13     CNS, PAIN MANAGEMENT AND GE & UROLOGY DEVICES MARKET PENETRATION IN U.S. NEUROMODULATION MARKET, 2019 (%)
      • FIGURE 14     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY PRODUCT (2019 V/S 2026) (%)
      • FIGURE 15     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 16     INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 17     INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
      • FIGURE 18     EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2019 V/S 2026) (%)
      • FIGURE 19     EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
      • FIGURE 20     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
      • FIGURE 21     PAIN MANAGEMENT GLOBAL MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
      • FIGURE 22     PAIN MANAGEMENT GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
      • FIGURE 23     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET SHARE, BY APPLICATION TYPE, (2019 V/S 2026) (%)
      • FIGURE 24     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
      • FIGURE 25     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET SHARE, BY APPLICATION TYPE, (2019 V/S 2026) (%)
      • FIGURE 26     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
      • FIGURE 27     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
      • FIGURE 28     HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC) GLOBAL MARKET SHARE, BY END-USERS, (2019 V/S 2026) (%)
      • FIGURE 29     CLINICS AND PHYSIOTHERAPY CENTERS GLOBAL MARKET SHARE, BY END-USERS, (2019 V/S 2026) (%)
      • FIGURE 30     ACADEMICS AND RESEARCH GLOBAL MARKET SHARE, BY END-USERS, (2019 V/S 2026) (%)
      • FIGURE 31     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN), CAGR (%)
      • FIGURE 32     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY GEOGRAPHY (2019) (%)
      • FIGURE 33     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BY PRODUCT, INTERNAL AND EXTERNAL NEUROMODULATION DEVICES BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 34     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BY APPLICATION AND PAIN MANAGEMENT BY APPLICATION TYPE (2019) (%)
      • FIGURE 35     NORTH AMERICA CNS, GASTROENTEROLOGY AND UROLOGY MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
      • FIGURE 36     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
      • FIGURE 37     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
      • FIGURE 38     U.S. NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 39     REST OF NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 40     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BY PRODUCT, INTERNAL AND EXTERNAL NEUROMODULATION DEVICES BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 41     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BY APPLICATION AND PAIN MANAGEMENT BY APPLICATION TYPE (2019) (%)
      • FIGURE 42     EUROPE CNS, GASTROENTEROLOGY AND UROLOGY MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
      • FIGURE 43     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
      • FIGURE 44     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
      • FIGURE 45     GERMANY NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 46     FRANCE NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 47     U.K. NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 48     REST OF EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 49     APAC NEUROMODULATION DEVICES MARKET SHARE, BY PRODUCT, INTERNAL AND EXTERNAL NEUROMODULATION DEVICES BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 50     APAC NEUROMODULATION DEVICES MARKET SHARE, BY APPLICATION AND PAIN MANAGEMENT BY APPLICATION TYPE (2019) (%)
      • FIGURE 51     APAC CNS, GASTROENTEROLOGY AND UROLOGY MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
      • FIGURE 52     APAC NEUROMODULATION DEVICES MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
      • FIGURE 53     APAC NEUROMODULATION DEVICES MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
      • FIGURE 54     JAPAN NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 55     CHINA NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 56     INDIA NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 57     REST OF APAC NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 58     ROW NEUROMODULATION DEVICES MARKET SHARE, BY PRODUCT, INTERNAL AND EXTERNAL NEUROMODULATION DEVICES BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 59     ROW NEUROMODULATION DEVICES MARKET SHARE, BY APPLICATION AND PAIN MANAGEMENT BY APPLICATION TYPE (2019) (%)
      • FIGURE 60     ROW CNS, GASTROENTEROLOGY AND UROLOGY MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
      • FIGURE 61     ROW NEUROMODULATION DEVICES MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
      • FIGURE 62     ROW NEUROMODULATION DEVICES MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
      • FIGURE 63     BRAZIL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 64     REST OF LATAM NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 65     MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
      • FIGURE 66     KEY GROWTH STRATEGIES, (2017-2019)
      • FIGURE 67     SWOT: ABBOTT LABORATORIES
      • FIGURE 68     SWOT: BEIJING PINS MEDICAL CO., LTD.
      • FIGURE 69     SWOT: BIONESS, INC.
      • FIGURE 70     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 71     SWOT: INSPIRE MEDICAL SYSTEM, INC.
      • FIGURE 72     SWOT: LABORIE MEDICAL TECHNOLOGY INC.
      • FIGURE 73     SWOT: LIVANOVA PLC
      • FIGURE 74     SWOT: MEDTRONIC PLC
      • FIGURE 75     SWOT: NEVRO CORPORATION
      • FIGURE 76     SWOT: NEUROPACE, INC.
      • FIGURE 77     SWOT: NUVECTRA CORPORATION

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABBOTT LABORATORIES
      • 2     ATES MEDICA DEVICE SRL
      • 3     ATROTECH OY
      • 4     AVERY BIOMEDICAL DEVICES INC.
      • 5     AXILUM ROBOTICS
      • 6     AXONICS MODULATION TECHNOLOGIES, INC.
      • 7     AXON THERAPIES, INC.
      • 8     BEIJING PINS MEDICAL CO., LTD.
      • 9     BIONESS INC.
      • 10     BIOCONTROL MEDICAL LTD.
      • 11     BIOINDUCTION LTD.
      • 12     BLUEWIND MEDICAL
      • 13     BOSTON SCIENTIFIC CORP.
      • 14     BRAINBOX LTD.
      • 15     BRAINSWAY
      • 16     CALA HEALTH
      • 17     CORTEC GMBH
      • 18     CVRX, INC.
      • 19     CYMEDICA ORTHOPEDICS
      • 20     DESYNCRA
      • 21     DJO GLOBAL (COLFAX)
      • 22     DW HEALTHCARE (CEFALY TECHNOLOGY)
      • 23     DYNAMD
      • 24     EB NEURO S.P.A.
      • 25     ELECTROCORE, INC.
      • 26     ENEURA INC.
      • 27     GIMER MEDICAL
      • 28     GTX MEDICAL
      • 29     HELIUS MEDICAL TECHNOLOGIES
      • 30     HEURO CANADA
      • 31     INNONCON MEDICAL
      • 32     INSPIRE MEDICAL SYSTEMS, INC.
      • 33     LABORIE MEDICAL SYSTEM INC.
      • 34     LIVANOVA PLC
      • 35     MAGSTIM TMS
      • 36     MAGVENTURE A/S
      • 37     MAINSTAY MEDICAL
      • 38     MEDTRONIC PLC
      • 39     METACURE, LTD.
      • 40     MICRO TRANSPONDER INC.
      • 41     NEVRO CORPORATION
      • 42     NEUROCARE GROUP GMBH
      • 43     NEUROELECTRICS
      • 44     NEUROLIEF LTD.
      • 45     NEURONANO AB
      • 46     NEURONETICS
      • 47     NEUROPACE INC.
      • 48     NEUROMETRIX, INC.
      • 49     NEUROMOD DEVICES LTD.
      • 50     NEUROS MEDICAL, INC.
      • 51     NEUROEM THERAPEUTICS
      • 52     IST, LLC (NEUROFUS)
      • 53     NEUROSIGMA INC.
      • 54     NEUROVALENS LTD. (MODIUS HEALTH)
      • 55     NEXSTIM, PLC
      • 56     NURALEVE INC.
      • 57     NUVECTRA
      • 58     NYXOAH SA
      • 59     OD STOCK MEDICAL
      • 60     ORCHESTRA BIOMED
      • 61     PATHMAKER NEUROSYSTEMS INC.
      • 62     PRECISIS AG
      • 63     REMED CO., LTD
      • 64     RESHAPE LIFESCIENCES, INC.
      • 65     RESPICARDIA, INC.
      • 66     SALUDA MEDICAL
      • 67     SCENERAY CORPORATION LTD.
      • 68     SET POINT MEDICAL
      • 69     SOOMA OY
      • 70     SPR THERAPEUTICS
      • 71     STIMWAVE LLC
      • 72     SYNAPSE BIOMEDICAL INC.
      • 73     SYNEIKA
      • 74     THERANICA BIO-ELECTRONICS LTD.
      • 75     TIVIC HEALTH
      • 76     TVNS TECHNOLOGIES GMBH
      • 77     YBRAIN, INC.
      • 78     ZYNEX MEDICAL, INC.